Quotes 5-day view Delayed Nyse
08/08/2022
08/09/2022
08/10/2022
08/11/2022
08/12/2022
Date
110.04(c)
108.13(c)
112.84(c)
109.94(c)
109.97(c)
Last
767 250
609 609
851 176
1 482 919
857 067
Volume
-0.47% -1.74% +4.36% -2.57% +0.03% Change
Estimated financial data (e) (USD)
Sales 2022
4 850 M - -
Net income 2022
481 M - -
Net Debt 2022
3 128 M - -
P/E ratio 2022
40,8x
Yield 2022
-
Sales 2023
5 289 M - -
Net income 2023
595 M - -
Net Debt 2023
2 909 M - -
P/E ratio 2023
34,0x
Yield 2023
-
Capitalization
19 708 M 19 708 M -
EV / Sales 2022
4,71x
EV / Sales 2023
4,28x
Nbr of Employees
17 300
Free-Float
99,7%
Catalent, Inc. is specialized in pharmaceutical outsourcing services. The group offers solutions for the development and formulation of drugs, biological products and animal health products. Net sales break down by activity as follows:
- subcontracted manufacturing services (46.4%)
- provision of development services (43.9%);
- clinical supply services (9.7%).
Net sales are distributed geographically as...
Ratings of Catalent, Inc.
All news about CATALENT, INC.
08/10 Catalent to Acquire Metrics Contract Services for $475 Million MT
08/09 Catalent to Acquire Metrics Contract Services for $475 Million to Expand High-Potent Ca.. BU
08/09 Catalent, Inc. agreed to acquire Metrics, Inc. from Mayne Pharma, Inc. for $475 million.. CI
08/08 Catalent, Inc. Announces Fourth Quarter Fiscal Year 2022 Earnings Conference Webcast AQ
08/05 Catalent, Inc. Announces Fourth Quarter Fiscal Year 2022 Earnings Conference Webcast BU
07/29 INSIDER SELL : CatalentMT
07/07 Xenetic Biosciences Signs Manufacturing Deal With Catalent Unit for Cancer Platform MT
07/05 Catalent Shifts to Two-Segment Structure; Names Jonathan Arnold Chief Commercial Office.. MT
07/05 CATALENT, INC. : Change in Directors or Principal Officers, Regulation FD Disclosure, Fina..AQ
07/05 Catalent, Inc. Announces Board Changes CI
07/05 Catalent Announces New Operating Structure BU
07/05 Catalent, Inc. Announces Executive Changes CI
06/30 Catalent Expands Primary Packaging Capabilities at its Clinical Supply Facility in Shig.. AQ
06/28 ISR signs development agreements with Catalent to scale-up its spray-dried nasal vaccin.. AQ
06/28 ISR Immune System Regulation Holding AB Signs Development Agreements with Catalent to S.. CI
News in other languages on CATALENT, INC.
Analyst Recommendations on CATALENT, INC.
Special Report-U.S. rushed contracts to COVID-19 suppliers with troubled plants
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends CATALENT, INC.
Short Term Mid-Term Long Term Trends Bullish Neutral Bearish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
BUY
Number of Analysts
14
Last Close Price
109,97 $
Average target price
134,92 $
Spread / Average Target
22,7%
Please enable JavaScript in your browser's settings to use dynamic charts.
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
